Navigation Links
HIKMA - 2008 Preliminary Results Interview With CEO
Date:3/17/2009

LONDON, March 17 /PRNewswire-FirstCall/ -- Hikma Pharmaceuticals today announced strong revenue growth and stable net profits despite a loss at the company's US Generics business. The weakness in the US was offset by a strong performance from the multinational Pharma company's Injectable and Branded businesses. CEO, Said Darwazah, said "The US operations, in 2007, reported operating profit of about $30m and in 2008 we had a loss there so in spite of this $30m plus loss the other divisions, the Branded and the Injectables, performed so well, grew so much that they were able to offset that."

Noting the current macro economic downturn Mr Darwazah said Hikma's diversified business model, both by geography and product, would support growth in 2009. "It's going to be a very, very tough year. And the way we're going to address this, as we said, is by controlled growth. Growth of 10% to 15%."

It's free to view. All you need to do is register at http://www.cantos.com. Cantos.com, the online financial broadcaster, features in-depth interviews, documentaries and webcasts with senior company executives. If you would like to contact us, please email enquiries@cantos.com or phone +44-207-936-1333.


'/>"/>
SOURCE HIKMA
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Hikma - 2007 Preliminary Results Interviews With CEO and CFO
2. Memry Corporation Announces Preliminary Fiscal Fourth Quarter and 2007 Revenue
3. YM BIOSCIENCES ANNOUNCES POSITIVE PRELIMINARY RESULTS FROM PHASE I/II LUNG CANCER TRIAL OF NIMOTUZUMAB COMBINED WITH RADIATION
4. BioCryst Reports Preliminary Results From a Phase II Clinical Trial of Peramivir in Subjects With Acute Influenza
5. CryoLife Announces Preliminary Third Quarter 2007 Revenues of Approximately $21.9 Million
6. Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook
7. Aidas Rh-Apo2L Clinical Testing Shows Preliminary Efficacy in Helping to Treat Lung Cancer, Stomach Cancer, Lymphoma, Pancreatic Cancer & Kidney Cancer
8. Tapestry Reports Third Quarter 2007 Financial Results and Preliminary Data From Its Phase 2 Prostate Cancer Trial
9. Symmetry Medical Reports Preliminary Third Quarter Revenue
10. KV Pharmaceutical Company Reports Record Revenues for Fiscal 2008 Second Quarter and Six Months on a Preliminary Basis
11. Sinovac Reports Top-Line Preliminary Phase II Results of Pandemic Influenza (H5N1) Whole Viron Vaccine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... January 15, 2014 Look inside the ... items for the lab, from fluid handling to instruments ... to ship when you order. , Preferred Solutions ... , from the L/S® model for precise flow control ...
(Date:1/15/2014)... California , January 15, 2014 Oxford ... today announced the appointment of Thomas C Reynolds MD, PhD ... years, development experience gained in the biotechnology industry, most recently ... am delighted to welcome Tom at this transformative time for ...
(Date:1/15/2014)... This webinar will focus on EMA and ... in biosimilars. , Regulatory frameworks are evolving many countries ... the complex nature of biopharmaceuticals makes the demonstration of ... challenging. Based on the specific aspects of biosimilar drug ...
(Date:1/15/2014)... More than 5 million Americans are currently ... seniors will die with Alzheimer’s or another dementia, according ... shocked many Americans into looking for ways to improve ... age-related cognitive disorders. Jonathan Weisman, president of Biohack Pure, ...
Breaking Biology Technology:Cole-Parmer Begins 2014 with the Release of Preferred Solutions 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 2Oxford BioTherapeutics Appoints Thomas C Reynolds MD, PhD to its Board of Directors 3Xtalks Life Sciences Webinar Examines Safety Assessment of Biosimilars 2Biohack Pure Offers 5 Tips for Increasing Memory in 2014 2
... Space ... the eighth scientific payload for Astrogenetix, a commercial biotech company created to use microgravity ... ... off from NASA’s Kennedy Space Center this morning, carrying on board the eighth scientific ...
... , Full enrollment occurs five months ahead of schedule , ... /PRNewswire-FirstCall/ - Resverlogix Corp. ("Resverlogix" or the "Company") (TSX:RVX) announced ... clinical study of its lead drug RVX-208. "The completion of ... months ahead of our original schedule, is a very exciting ...
... , , , , ... Feb. 8 /PRNewswire-Asia-FirstCall/ -- 3SBio Inc. (Nasdaq:, ... China -based biotechnology company,focused on researching, developing, manufacturing and ... Panacor Bioscience Ltd. to develop and commercialize its,Nephoxil(R) pharmaceutical ...
Cached Biology Technology:Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 2Astrogenetix Continues MRSA Vaccine Development Onboard Endeavor 3Resverlogix Completes Patient Recruitment for ASSERT Trial 2Resverlogix Completes Patient Recruitment for ASSERT Trial 3Resverlogix Completes Patient Recruitment for ASSERT Trial 43SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 23SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 33SBio and Panacor Bioscience Enter Collaboration and License Agreement to Develop and Commercialize Nephoxil(R) for Hyperphosphatemia 4
(Date:4/20/2014)... Neb., April 20, 2014 -- Using corn crop residue ... and can generate more greenhouse gases than gasoline, according ... Nature Climate Change . , The findings by a ... whether corn residue can be used to meet federal ... gas emissions. , Corn stover -- the stalks, leaves ...
(Date:4/18/2014)... have used techniques like X-ray crystallography and nuclear magnetic ... atomic structure of molecules, but such efforts have long ... quantities of a specific molecule and often in ordered ... all but impossible to peer into the structure of ... may soon be a thing of the past. ...
(Date:4/18/2014)... For the past 20 years, researchers have published ... research findings have suggested that soil organic carbon can ... tillage systems to no-till systems. However, there is a ... in corn and soybean rotations without cover crops, small ... carbon stocks at the published rates. , "Some studies ...
Breaking Biology News(10 mins):Study casts doubt on climate benefit of biofuels from corn residue 2Study casts doubt on climate benefit of biofuels from corn residue 3MRI, on a molecular scale 2MRI, on a molecular scale 3Researchers question published no-till soil organic carbon sequestration rates 2Researchers question published no-till soil organic carbon sequestration rates 3Researchers question published no-till soil organic carbon sequestration rates 4
... College of Medical Genetics (ACMG) will hold its 16th ... Sunday, March 29, 2009 at the Tampa Convention Center. ... healthcare is evolving at a dizzying pace and the ... opportunity for the medical and scientific media to learn ...
... then eating less may help you live longer. For ... of a new study predict the anti-aging strategy known ... dangerous exercise. "Today there are a lot of very ... this," said Raj Sohal, professor at the University of Southern ...
... A new strategy developed in the Neonatal and Infant ... premature infants and other newborns with severe swallowing difficulties ... study appearing in the February issue of the ... Nationwide Children,s were able to help 15 out of ...
Cached Biology News:Far-reaching genetics topics to be addressed: 2009 Annual Clinical Genetics Meeting, March 25-29 2Eating less may not extend life 2Crib-side studies help struggling newborns go home without feeding tubes 2Crib-side studies help struggling newborns go home without feeding tubes 3
Anti-Bcl-G (CT) Host: rabbit polyclonal Species Reactivity: human, mouse, rat Applications: WB, IHC Storage: 4C...
Mouse anti-IkBa/MAD-3 Class: Antibody Product Group: Signalling molecules and phospho-specific Antibody...
Rabbit polyclonal to Oct2, prediluted ( Abpromise for all tested applications). entrezGeneID: 5452 SwissProtID: P09086...
Anti-Mouse Reticular Fibroblast, Purified (Clone ER-TR7) (rat IgG2a)...
Biology Products: